Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Heterozygous p53V172F mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53

Abstract

Cisplatin is an important antitumor agent, but its clinical utility is often limited by multifactorial mechanism of resistance. Loss of tumor suppressor p53 function is a major mechanism that is affected by either mutation in the DNA-binding domain or dysregulation by overexpression of p53 inhibitors MDM2 and MDM4, which destabilize p53 by increasing its proteosomal degradation. In the present study, cisplatin-resistant 2780CP/Cl-16 ovarian tumor cells expressed a heterozygous, temperature-sensitive p53V172F mutation, which reduced p53 half-life by two- to threefold compared with homozygous wild-type (wt) p53 in parental A2780 cells. Although reduced p53 stability in 2780CP/Cl-16 cells was associated with moderate cellular overexpression of MDM2 or MDM4 (<1.5-fold), their binding to p53 was substantially enhanced (five- to eightfold). The analogous cisplatin-resistant 2780CP/Cl-24 cells, which express loss of p53 heterozygosity, retained the p53V172F mutation and high p53-MDM4 binding, but demonstrated lower p53-bound MDM2 that was associated with reduced p53 ubiquitination and enhanced p53 stability. The inference that p53 was unstable as a heteromeric p53wt/p53V172F complex was confirmed in 2780CP/Cl-24 cells transfected with wt p53 or multimer-inhibiting p53L344P mutant, and further supported by normalization of p53 stability in both resistant cell lines grown at the permissive temperature of 32.5 °C. Surprisingly, in 2780CP/Cl-16 and 2780CP/Cl-24 models, cisplatin-induced transactivity of p53 was attenuated at 37 °C, and this correlated with cisplatin resistance. However, downregulation of MDM2 or MDM4 by small interfering RNA in either resistant cell line induced p53 and restored p21 transactivation at 37 °C, as did cisplatin-induced DNA damage at 32.5 °C that coincided with reduced p53-MDM4 binding and cisplatin resistance. These results demonstrate that cisplatin-mediated p53V172F mutation regulates p53 stability at the normothermic temperature, but it is the increased recruitment of MDM4 by the homomeric or heteromeric mutant p53V172F complex that inhibits p53-dependent transactivation. This represents a novel cellular mechanism of p53 inhibition, and, thereby, induction of cisplatin resistance.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Martinez-Rivera M, Siddik ZH . Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem Pharmacol 2012; 83: 1049–1062.

    Article  CAS  PubMed  Google Scholar 

  2. Toledo F, Wahl GM . MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 2007; 39: 1476–1482.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Perry ME . The regulation of the p53-mediated stress response by MDM2 and MDM4. Cold Spring Harb Perspect Biol 2010; 2: a000968.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Wang X, Jiang X . Mdm2 and MdmX partner to regulate p53. FEBS Lett 2012; 586: 1390–1396.

    Article  CAS  PubMed  Google Scholar 

  5. Pei D, Zhang Y, Zheng J . Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget 2012; 3: 228–235.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Okamoto K, Kashima K, Pereg Y, Ishida M, Yamazaki S, Nota A et al. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol 2005; 25: 9608–9620.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chen L, Gilkes DM, Pan Y, Lane WS, Chen J . ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J 2005; 24: 3411–3422.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kawai H, Wiederschain D, Kitao H, Stuart J, Tsai KK, Yuan ZM . DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem 2003; 278: 45946–45953.

    Article  CAS  PubMed  Google Scholar 

  9. Kondo S, Barnett GH, Hara H, Morimura T, Takeuchi J . MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 1995; 10: 2001–2006.

    CAS  PubMed  Google Scholar 

  10. Cocker HA, Hobbs SM, Tiffin N, Pritchard-Jones K, Pinkerton CR, Kelland LR . High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Br J Cancer 2001; 85: 1746–1752.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lam S, Lodder K, Teunisse AF, Rabelink MJ, Schutte M, Jochemsen AG . Role of Mdm4 in drug sensitivity of breast cancer cells. Oncogene 2010; 29: 2415–2426.

    Article  CAS  PubMed  Google Scholar 

  12. Mujoo K, Watanabe M, Nakamura J, Khokhar AR, Siddik ZH . Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. J Cancer Res Clin Oncol 2003; 129: 709–718.

    Article  CAS  PubMed  Google Scholar 

  13. Siddik ZH, Mims B, Lozano G, Thai G . Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res 1998; 58: 698–703.

    CAS  PubMed  Google Scholar 

  14. Lu X, Errington J, Curtin NJ, Lunec J, Newell DR . The impact of p53 status on cellular sensitivity to antifolate drugs. Clin Cancer Res 2001; 7: 2114–2123.

    CAS  PubMed  Google Scholar 

  15. Komlodi-Pasztor E, Trostel S, Sackett D, Poruchynsky M, Fojo T . Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells. Oncogene 2009; 28: 3111–3120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Yazlovitskaya EM, DeHaan RD, Persons DL . Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem Biophys Res Commun 2001; 283: 732–737.

    Article  CAS  PubMed  Google Scholar 

  17. Gaglia G, Guan Y, Shah JV, Lahav G . Activation and control of p53 tetramerization in individual living cells. Proc Natl Acad Sci USA 2013; 110: 15497–15501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Davison TS, Yin P, Nie E, Kay C, Arrowsmith CH . Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. Oncogene 1998; 17: 651–656.

    Article  CAS  PubMed  Google Scholar 

  19. Tsvetkov P, Reuven N, Shaul Y . Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ 2010; 17: 103–108.

    Article  CAS  PubMed  Google Scholar 

  20. Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG et al. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem 2002; 277: 19251–19254.

    Article  CAS  PubMed  Google Scholar 

  21. Mancini F, Gentiletti F, D'Angelo M, Giglio S, Nanni S, D'Angelo C et al. MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis. J Biol Chem 2004; 279: 8169–8180.

    Article  CAS  PubMed  Google Scholar 

  22. Siddik ZH . Cisplatin resistance: molecular basis of a multifactorial impediment. In: Teicher BA (ed). Cancer Drug Resistance. Humana Press: Totowa, NJ, USA, 2006, pp 283–307.

    Chapter  Google Scholar 

  23. Wang YV, Wade M, Wong E, Li YC, Rodewald LW, Wahl GM . Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc Natl Acad Sci USA 2007; 104: 12365–12370.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Brachova P, Thiel KW, Leslie KK . The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci 2013; 14: 19257–19275.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008; 22: 1337–1344.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lenos K, Jochemsen AG . Functions of MDMX in the modulation of the p53-response. J Biomed Biotechnol 2011; 2011: 876173.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Kuang J, He G, Huang Z, Khokhar AR, Siddik ZH . Bimodal effects of 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) on cell cycle checkpoints. Clin Cancer Res 2001; 7: 3629–3639.

    CAS  PubMed  Google Scholar 

  28. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009; 325: 1134–1138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sdek P, Ying H, Chang DL, Qiu W, Zheng H, Touitou R et al. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 2005; 20: 699–708.

    Article  CAS  PubMed  Google Scholar 

  30. He G, Kuang J, Khokhar AR, Siddik ZH . The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog. Gynecol Oncol 2011; 122: 402–409.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. He G, Kuang J, Koomen J, Kobayashi R, Khokhar AR, Siddik ZH . Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents. Br J Cancer 2013; 109: 2378–2388.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The research support from the US Public Health Service Grants CA160687 to ZHS and Support Grant CA16672 to MD Anderson Cancer Center, awarded by the National Cancer Institute, and in part from the Megan McBride Franz Endowed Research Fund, is gratefully acknowledged. We thank Dr Shiaw-Yih Lin (MD Anderson Cancer Center) for the His-Ubiquitin plasmid, and also Dr Guangan He and Michelle Martinez for helpful discussions.

Author contributions

XX, GL and ZHS designed and/or executed the experiments, and analyzed and interpreted the data. XX and ZHS wrote the initial draft of the manuscript, and GL contributed to revision for the final version.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Z H Siddik.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xie, X., Lozano, G. & Siddik, Z. Heterozygous p53V172F mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene 35, 4798–4806 (2016). https://doi.org/10.1038/onc.2016.12

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2016.12

This article is cited by

Search

Quick links